Please login to the form below

Not currently logged in


This page shows the latest CTCL news and features for those working in and with pharma, biotech and healthcare.

New leader at Medivir after setbacks

New leader at Medivir after setbacks

lead compound remetinostat, intended as a treatment for early-stage cutaneous T-cell lymphoma (CTCL), because it couldn’t agree on a design with the FDA. ... Medivir bought the rights to remetinostat from TetraLogic Pharma for $12m upfront in November

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐ cell lymphoma [CTCL].

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    387. Ceptaris Therapeutics / Actelion. Acquisition. Valchlor for mycosis fungoides-type CTCL (NDA). ... CTCL = cutaneous T-cell lymphoma. VLP  = virus-like particle produced in plant expression systems .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...